What is RedShiftBio?
RedShiftBio is a specialized provider of advanced analytical instrumentation designed for the research, development, and manufacturing of protein-based therapeutics. At the core of its value proposition is the patented Microfluidic Modulation Spectroscopy (MMS) technology. This breakthrough analytical technique allows for the direct, high-resolution probing of the biophysical structure of proteins. By consolidating five key measurements into a single, automated workflow, the company effectively eliminates the inefficiencies associated with traditional, multi-instrument testing protocols. This technological edge positions RedShiftBio as an indispensable partner for biopharmaceutical organizations seeking to accelerate the time-to-market for complex protein drugs while ensuring stringent quality control and structural integrity.
How much funding has RedShiftBio raised?
RedShiftBio has raised a total of $71.7M across 9 funding rounds:
Series B
$6.2M
Private Equity
$2.4M
Private Equity
$751K
Private Equity
$1M
Series C
$11M
Series D
$18M
Debt
$350K
Series E
$20M
Series B (2008): $6.2M led by Emerson Ventures, Technology Venture Partners, InterWest Partners, and Alta California Partners
Private Equity (2012): $2.4M, investors not publicly disclosed
Private Equity (2014): $751K featuring Technology Venture Partners, LLC
Private Equity (2015): $998K, investors not publicly disclosed
Series C (2017): $11M with participation from Technology Venture Partners and Waters
Series D (2020): $18M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series E (2021): $20M featuring Technology Venture Partners, Illumina Ventures, and Waters
Key Investors in RedShiftBio
Technology Venture Partners
Technology Venture Partners is dedicated to accelerating innovators and entrepreneurs through active investment in high-potential technology companies, focusing on growth-equity to guide firms toward market leadership.
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health and biopharmaceutical development.
Waters
Waters is a global leader in analytical instrumentation and software, providing scientific insights that improve human health by ensuring the safety and quality of medicines and everyday products.
What's next for RedShiftBio?
With the successful closure of its most recent strategic investment, RedShiftBio is well-positioned to accelerate the commercial adoption of its MMS platform across global life science markets. The company is expected to leverage this capital to expand its R&D capabilities, further refining its instrumentation to meet the evolving complexities of next-generation protein therapeutics. Strategic focus will likely remain on deepening its integration within the biopharmaceutical manufacturing ecosystem, where the demand for automated, high-precision structural analysis continues to rise. As the firm scales, it will likely prioritize the expansion of its commercial footprint, ensuring that its proprietary technology becomes the industry standard for protein characterization and quality assurance in clinical and commercial settings.
See full RedShiftBio company page
